Pregabalin Tablet Treats Neuropathic Pain in Canines
Summary
USPTO published patent application US20260108484A1 for a veterinary tablet immediate-release formulation comprising approximately 25% by weight of pregabalin, 5-15% meat flavour, 58-69% microcrystalline cellulose, and 1-2% magnesium stearate as a lubricant, designated for treating neuropathic pain in non-human animals (canines). The application was originally filed on September 8, 2023 (Application No. 19116857) by TriviumVet Designated Activity Company. For pharmaceutical manufacturers, animal health companies, and veterinary drug developers, this publication establishes the priority date and claims scope for freedom-to-operate analysis.
“A veterinary tablet immediate release formulation comprising: about 25% by weight of pregabalin; from 5% to 15% by weight of a meat flavour; from 58% to 69% by weight of microcrystalline cellulose; and from 1% to 2% by weight of a lubricant such as magnesium stearate.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
USPTO published patent application US20260108484A1, a new veterinary pharmaceutical formulation patent covering an immediate-release tablet containing about 25% pregabalin by weight, combined with meat flavour, microcrystalline cellulose, and magnesium stearate as excipients, for treating neuropathic pain in canines. The invention is owned by TriviumVet Designated Activity Company.
For animal health companies, veterinary pharmaceutical manufacturers, and competitive intelligence teams, this publication marks the beginning of the patent's public examination period. Competitors developing similar veterinary analgesic formulations should conduct freedom-to-operate analyses before commercializing products in this space. Veterinary drug developers may consider licensing negotiations or designing around the claimed composition.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TREATMENT OF NEUROPATHIC PAIN IN CANINES
Application US20260108484A1 Kind: A1 Apr 23, 2026
Assignee
TRIVIUMVET DESIGNATED ACTIVITY COMPANY
Inventors
Stuart FITZGERALD, Tom BRENNAN, Louise GRUBB, Liam BYRNE
Abstract
A veterinary tablet immediate release formulation comprising: about 25% by weight of pregabalin; from 5% to 15% by weight of a meat flavour; from 58% to 69% by weight of microcrystalline cellulose; and from 1% to 2% by weight of a lubricant such as magnesium stearate. Said composition for use in treating neuropathic pain in a non-human animal.
CPC Classifications
A61K 31/197 A61K 9/2013 A61K 9/2054 A61P 25/02
Filing Date
2023-09-08
Application No.
19116857
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.